Durvalumab Plus Tarlatamab Improves Overall Survival in First-Line Extensive-Stage Small Cell Lung Cancer
Sep 08, 2026
View online
Durvalumab Plus Tarlatamab Improves Overall Survival in First-Line Extensive-Stage Small Cell Lung Cancer
Elizabeth Mittendorf: Grateful to Represent ASCO at the KSMO Annual Meeting in Seoul
David Planchard: New Biomarkers and Treatment Strategies in Advanced NSCLC
Sumanta K. Pal: Misalignment Between Clinical Trial Access and Disease Burden in US Bladder Cancer
GC-OS 2026: Where Cardio-Oncology Looks to the Future
New Zealanders Have Spoken, Cancer Action Has a Public Mandate – Cancer Society of New Zealand
Asparaginase: The Unexpected Discovery Behind a Cornerstone of ALL Treatment
CDMRP Kidney Cancer Academy Early-Career Scholar Award 2026
CDMRP Ovarian Cancer Academy Early-Career Investigator Award 2026
Molecular Analysis for Precision Oncology Congress 2026
Optimising Antibody–Drug Conjugate Safety: Mechanisms, Monitoring and Management of Toxicities 2026
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
